(Q38734441)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27416986%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

review article

1 reference

title

A review of new agents evaluated against pediatric acute lymphoblastic leukemia by the Pediatric Preclinical Testing Program (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27416986%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

1 reference

lymphoblastic leukemia

1 reference

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27416986%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

Richard B Lock

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27416986%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

author name string

L Jones

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27416986%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

H Carol

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27416986%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

K Evans

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27416986%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

J Richmond

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27416986%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

P J Houghton

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27416986%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

publication date

15 July 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27416986%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27416986%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

volume

30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27416986%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27416986%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

page(s)

2133-2141

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27416986%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/leu.2016.192

18 March 2020

exact match

0 references

cites work

Cell and molecular determinants of in vivo efficacy of the BH3 mimetic ABT-263 against pediatric acute lymphoblastic leukemia xenografts

1 reference

12 December 2020

Testing of the topoisomerase 1 inhibitor Genz-644282 by the pediatric preclinical testing program.

1 reference

12 December 2020

Initial testing (stage 1) of the phosphatidylinositol 3' kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program.

1 reference

12 December 2020

Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP).

1 reference

12 December 2020

Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program.

1 reference

12 December 2020

Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study

1 reference

12 December 2020

Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program

1 reference

12 December 2020

Evaluation of the in vitro and in vivo efficacy of the JAK inhibitor AZD1480 against JAK-mutated acute lymphoblastic leukemia

1 reference

12 December 2020

Pronounced hypoxia in models of murine and human leukemia: high efficacy of hypoxia-activated prodrug PR-104

1 reference

12 December 2020

The anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse postinduction therapy in preclinical models of pediatric acute lymphoblastic leukemia.

1 reference

12 December 2020

The PI3K/PKB signaling module as key regulator of hematopoiesis: implications for therapeutic strategies in leukemia.

1 reference

12 December 2020

IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer

1 reference

12 December 2020

Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program

1 reference

12 December 2020

Regulatory approvals of pediatric oncology drugs: previous experience and new initiatives

1 reference

12 December 2020

Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a γ-secretase inhibitor targeting notch signaling

1 reference

12 December 2020

Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program

1 reference

12 December 2020

Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing Program

1 reference

12 December 2020

Pharmacokinetic modeling of an induction regimen for in vivo combined testing of novel drugs against pediatric acute lymphoblastic leukemia xenografts.

1 reference

12 December 2020

Chimeric antigen receptor T cells for sustained remissions in leukemia

1 reference

12 December 2020

Evaluation of cis-dichlorodiammineplatinum(II) in children with advanced malignant diseases: Southwest Oncology Group Studies

1 reference

12 December 2020

Targeting the Bcl-2 family for cancer therapy

1 reference

12 December 2020

Initial testing (stage 1) of LCL161, a SMAC mimetic, by the Pediatric Preclinical Testing Program

1 reference

12 December 2020

Next generation oncology drug development: opportunities and challenges

1 reference

12 December 2020

Dose escalation of lenalidomide in relapsed or refractory acute leukemias

1 reference

12 December 2020

Initial testing of cisplatin by the pediatric preclinical testing program

1 reference

12 December 2020

Oncogenic Flt3 receptors display different specificity and kinetics of autophosphorylation

1 reference

12 December 2020

Pediatric phase I trial and pharmacokinetic study of MLN8237, an investigational oral selective small-molecule inhibitor of Aurora kinase A: a Children's Oncology Group Phase I Consortium study

1 reference

12 December 2020

Initial testing of the CENP-E inhibitor GSK923295A by the pediatric preclinical testing program

1 reference

12 December 2020

Targeting apoptosis pathways in cancer therapy

1 reference

12 December 2020

Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia

1 reference

12 December 2020

Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in Leukemia Study Group

1 reference

12 December 2020

Phase I and pharmacokinetic study of topotecan administered orally once daily for 5 days for 2 consecutive weeks to pediatric patients with refractory solid tumors

1 reference

12 December 2020

Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development

1 reference

12 December 2020

Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673.

1 reference

12 December 2020

Credentialing preclinical pediatric xenograft models using gene expression and tissue microarray analysis

1 reference

12 December 2020

Effective targeting of the P53-MDM2 axis in preclinical models of infant MLL-rearranged acute lymphoblastic leukemia

1 reference

12 December 2020

Initial testing (stage 1) of AZD6244 (ARRY-142886) by the Pediatric Preclinical Testing Program.

1 reference

12 December 2020

Mutations and deletions of the TP53 gene predict nonresponse to treatment and poor outcome in first relapse of childhood acute lymphoblastic leukemia

1 reference

12 December 2020

Initial testing of lenalidomide by the pediatric preclinical testing program

1 reference

12 December 2020

Cancer statistics, 2009

1 reference

12 December 2020

KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia.

1 reference

12 December 2020

Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the Pediatric Preclinical Testing Program

1 reference

12 December 2020

New insights into drug development for pediatric solid tumors: what preclinical data justify clinical trials in pediatric cancer?

1 reference

12 December 2020

New drugs for children and adolescents with cancer: the need for novel development pathways.

1 reference

12 December 2020

Challenging issues in pediatric oncology

1 reference

12 December 2020

Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17-DMAG, KOS-1022) by the pediatric preclinical testing program.

1 reference

12 December 2020

Analysis of p53 mutations in a large series of lymphoid hematologic malignancies of childhood

1 reference

12 December 2020

Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes

1 reference

12 December 2020

A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children's Oncology Group study.

1 reference

12 December 2020

Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program

1 reference

12 December 2020

Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program.

1 reference

12 December 2020

Targeting BCL2 for the treatment of lymphoid malignancies

1 reference

12 December 2020

Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program.

1 reference

12 December 2020

Initial testing (Stage 1) of AT13387, an HSP90 inhibitor, by the pediatric preclinical testing program.

1 reference

12 December 2020

Quantitative phosphotyrosine profiling of patient-derived xenografts identifies therapeutic targets in pediatric leukemia.

1 reference

12 December 2020

Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program.

1 reference

12 December 2020

Initial testing (stage 1) of mapatumumab (HGS-ETR1) by the pediatric preclinical testing program

1 reference

12 December 2020

The pediatric preclinical testing program: description of models and early testing results.

1 reference

12 December 2020

Declining childhood and adolescent cancer mortality

1 reference

12 December 2020

Initial testing (stage 1) of the Akt inhibitor GSK690693 by the pediatric preclinical testing program.

1 reference

12 December 2020

Curaxins: anticancer compounds that simultaneously suppress NF-κB and activate p53 by targeting FACT.

1 reference

12 December 2020

Molecular characterization of the pediatric preclinical testing panel

1 reference

12 December 2020

Long-term outcomes in survivors of childhood acute lymphoblastic leukemia

1 reference

12 December 2020

AZD1480: a phase I study of a novel JAK2 inhibitor in solid tumors

1 reference

12 December 2020

Testing of new agents in childhood cancer preclinical models: meeting summary

1 reference

12 December 2020

Initial testing of aplidin by the pediatric pre-clinical testing program.

1 reference

12 December 2020

AKR1C3 is a biomarker of sensitivity to PR-104 in preclinical models of T-cell acute lymphoblastic leukemia

1 reference

12 December 2020

Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program.

1 reference

12 December 2020

High drug attrition rates--where are we going wrong?

1 reference

12 December 2020

Initial testing (stage 1) of the notch inhibitor PF-03084014, by the pediatric preclinical testing program

1 reference

12 December 2020

Testing of the Akt/PKB inhibitor MK-2206 by the Pediatric Preclinical Testing Program.

1 reference

12 December 2020

Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program

1 reference

12 December 2020

Sensitivity toward sorafenib and sunitinib varies between different activating and drug-resistant FLT3-ITD mutations

1 reference

12 December 2020

Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program.

1 reference

12 December 2020

Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program.

1 reference

12 December 2020

Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia

1 reference

12 December 2020

Initial testing of the MDM2 inhibitor RG7112 by the Pediatric Preclinical Testing Program

1 reference

12 December 2020

Initial testing (stage 1) of the polyamine analog PG11047 by the pediatric preclinical testing program.

1 reference

12 December 2020

Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program

1 reference

12 December 2020

Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study

1 reference

12 December 2020

Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program

1 reference

12 December 2020

Initial testing (stage 1) of the Polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program.

1 reference

12 December 2020

Initial testing (stage 1) of SGI-1776, a PIM1 kinase inhibitor, by the pediatric preclinical testing program.

1 reference

12 December 2020

Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program.

1 reference

12 December 2020

A novel fluorometric assay for aldo-keto reductase 1C3 predicts metabolic activation of the nitrogen mustard prodrug PR-104A in human leukaemia cells

1 reference

12 December 2020

Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report

1 reference

12 December 2020

Pharmacokinetic-pharmacodynamic analysis of vismodegib in preclinical models of mutational and ligand-dependent Hedgehog pathway activation

1 reference

12 December 2020

Efficacy of CPX-351, (cytarabine:daunorubicin) liposome injection, against acute lymphoblastic leukemia (ALL) xenograft models of the Pediatric Preclinical Testing Program

1 reference

12 December 2020

Recent research advances in childhood acute lymphoblastic leukemia

1 reference

12 December 2020

New markers for minimal residual disease detection in acute lymphoblastic leukemia

1 reference

12 December 2020

Initial testing of topotecan by the pediatric preclinical testing program.

1 reference

12 December 2020

Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia (TACL) consortium

1 reference

12 December 2020

Initial testing of dasatinib by the pediatric preclinical testing program

1 reference

12 December 2020

High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses.

1 reference

12 December 2020

Antibody therapy for pediatric leukemia.

1 reference

12 December 2020

Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer.

1 reference

12 December 2020

Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program

1 reference

12 December 2020

Approved monoclonal antibodies for cancer therapy

1 reference

12 December 2020

Protracted intermittent schedule of topotecan in children with refractory acute leukemia: a pediatric oncology group study

1 reference

12 December 2020

Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies

1 reference

12 December 2020

Initial testing (stage 1) of lapatinib by the pediatric preclinical testing program

1 reference

12 December 2020

Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study

1 reference

12 December 2020